EUROBIO SCIENTIFIC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.1 EUR | +2.17% |
|
+0.14% | -14.34% |
| Jun. 24 | Proteomics International Laboratories Taps French Distributor for Diabetic Kidney Disease Test | MT |
| May. 08 | Eurobio Scientific: agreement with Myriad Genetics | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.95 for the current period. Therefore, the company is undervalued.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.34% | 150M | - | ||
| +17.09% | 45.34B | B- | ||
| +42.10% | 40.42B | A | ||
| -9.70% | 37.92B | B | ||
| +33.28% | 31.75B | B | ||
| -8.98% | 27.71B | C | ||
| +13.37% | 26.52B | B- | ||
| +44.11% | 13.96B | B+ | ||
| +32.33% | 12.44B | C+ | ||
| -7.26% | 11.26B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ALERS Stock
- Ratings Eurobio Scientific
